News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Clavis Pharma ASA Stops Elacytarabine Development on Negative Ph3 Trial in AML


4/2/2013 7:56:18 AM

Clavis Pharma ASA (CLAVIS), a Norwegian biotech, is considering closing or selling itself to another company after its experimental leukemia treatment elacytarabine failed in a late-stage trial. Clavis has a short-list of Scandinavian private companies that may be interested in taking it over and will approach them over the next few weeks, Chief Executive Officer Olav Helleboe said on a conference call today. All development work on elacytarabine has been suspended, the Oslo-based company said in a statement yesterday. The study, which didn’t show a significant difference in survival rates between patients who received elacytarabine and those taking other treatments, follows similar results from a trial on a Clavis pancreatic cancer treatment in November. Both drugs were aimed at improving existing medicines by using Clavis’s own Lipid Vector Technology.

Read at Bloomberg
Read at News Release


comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES